TB-Related News and Journal Items Weekly Update
Week of January 16 to January 22, 2011
CDC provides the TB-Related News and Journal Items Weekly Update as a public service only.
This update is a compilation of TB-related articles published for the benefit and information of
people interested in TB, and we do not confirm the accuracy of the data in the articles that are
abstracted. Providing synopses of key scientific articles and lay media reports on TB does not
constitute CDC endorsement. This update may also include information from CDC and other
government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR)
articles, fact sheets, press releases, and announcements. Reproduction of this text is
encouraged; however, copies may not be sold. For those items reproduced from the first section
of the TB weekly update, the CDC HIV/Hepatitis/STD/TB Prevention News Update should be
cited. For any other items in the TB weekly update, you may cite the CDC TB-Related News
and Journal Items Weekly Update.
This Week's Contents
TB-Related Announcements
News Item(s) From the CDC HIV/Hepatitis/STD/TB Prevention News Update
Headlines
Journal Articles
Job Announcements
Upcoming Conferences, Trainings, and Other Events
TB-Related Announcements
1. ―Asking the Right Questions: A Visual Guide to Tuberculosis Case
Management for Nurses‖ now available online
The Francis J. Curry National TB Center announces a new online educational
toolkit: Asking the Right Questions: A Visual Guide to Tuberculosis Case
Management for Nurses (http://www.nationaltbcenter.ucsf.edu/arq/index.cfm) .
The primary target audience is nurses in the public and private health sectors,
but the toolkit materials are also useful for TB outreach workers, health care
workers in facilities where TB cases are found, and community-based providers
who may identify TB suspects or help to treat patients with TB.
Learners can use the toolkit to:
Prompt critical thinking about TB case management
Find relevant basic national training materials and guidelines
Get an overview of the full TB case management timeline
The toolkit can be used for self-paced learning or for mixed classroom and self-
paced learning. It has three components:
(1)The Visual Guide (poster) presents a timeline of the full TB case management
process and suggests critical questions to ask throughout the process to ensure
full assessment of TB suspects and completion of safe, effective treatment for
TB disease.
(2) The Reference Guide takes the critical questions another level deeper and
offers short topics that briefly explain relevant concepts, and provides
hyperlinks to training materials from the CDC and Regional Training and Medical
Consultation Centers and to current national guidelines and selected
publications.
(3) The Web Guide offers several features for exploring questions and concepts.
These features include: an interactive exploration of critical questions linking to
Reference Guide topics and hyperlinks, a presentation about the TB case
management timeline that is part of the Visual Guide, an online glossary, and
downloadable learning guides with suggested curricula.
To put these materials to use, two learning guides suggest training curricula for
self-paced learning and for a combination of self-paced and classroom-based
learning, adaptable to the needs of your jurisdiction or agency. The Facilitator’s
Guide offers suggestions for presenting a curriculum that combines self-paced
study with classroom discussion and activities. The Self-Paced Learning Guide
outlines a learning curriculum that can be completed by the learner at his or her
own pace.
2. TB REACH Launches Call for Proposals for Wave 2 Funding
Stop TB Partnership, December 1, 2010
TB REACH is accepting proposals for the second wave of funding for projects
that promote early and increased case detection of TB cases and ensure their
timely treatment, while maintaining high cure rates within national TB programs.
TB REACH encourages the development and application of innovative, ground-
breaking, and efficient approaches, interventions, and activities that result in
increased TB case detection, reduced transmission, and prevention of the
emergence of drug-resistant forms of TB. As suggested by its name, TB REACH
focuses on reaching vulnerable people, people from poverty areas, and people
who have limited or no access to TB services.
Eligibility criteria, examples of suitable interventions, technical guidance, the
application form, and instructions for applicants are available on the TB REACH
website.
The deadline for submitting proposals for Wave 2 is February 28, 2011.
Eligible applications will be reviewed by the Proposal Review Committee, an
independent group of experts, during March 2011. All proposals recommended
for funding will be presented for approval to the Stop TB Partnership
Coordinating Board at its next meeting. The final results of the review are likely
to be made available to all applicants by May 2011.
TB REACH was launched officially on January 25, 2010. Thirty projects in 19
eligible countries, which aimed to detect and treat an additional 40,000 new
smear-positive TB cases, received funding under Wave 1. The TB REACH
initiative receives support from the Canadian International Development Agency
(CIDA).
News Item(s) From the CDC HIV/Hepatitis/STD/TB Prevention News Update
1. West Fargo Students Warned of Possible Exposure to Tuberculosis
WDAY.com (Fargo), January 13, 2011
Parents of 75 students who attend a school in West Fargo, North Dakota, have
been notified that their children likely have had direct contact with a student who
has symptoms of active TB, although that diagnosis has not been confirmed.
The only students potentially at risk are those whose parents received the
letters, said Dr. John Baird, health officer. The students who undergo testing will
be tested again in eight to 10 weeks, Baird said.
Headlines
1. New Executive Secretary to Head the Stop TB Partnership (Switzerland)
Stop TB Partnership, www.stoptb.org, January 19, 2011
The Stop TB Partnership announced the appointment of Dr. Lucica Ditiu as its
Executive Secretary, replacing Dr. Marcos Espinal, who stepped down in August
of 2010. Dr. Ditiu is a physician and researcher who has focused on improving
the lives of people living in communities heavily burdened by TB. She joined the
Stop TB Partnership in Geneva in January of 2010 to lead the TB REACH
initiative. She began working with the World Health Organization (WHO) in
January of 2000 as a medical officer for TB in Albania, Kosovo, and Macedonia
within the disaster and preparedness unit of the WHO European Regional Office.
Dr. Ditiu is a 1992 graduate of the University of Medicine and Pharmacy in
Bucharest, and completed a specialty in pulmonology in a joint program with the
Romanian National Institute of Lung Disease. In 1999, she received a certificate
in International Public Health from the George Washington University in
Washington, DC, where she completed a fellowship in the epidemiology of lung
disease in TB control and program management and evaluation.
2. Stop TB Partnership Global Drug Facility (GDF) Working to Mitigate Shortage
of Quality-Assured Streptomycin (Switzerland)
Stop TB Partnership, www.stoptb.org, January 17, 2011
The Global Drug Facility (GDF) will resume streptomycin delivery in the first
quarter of 2011 in limited supply until at least mid-2011. Allocation of stocks to
existing GDF orders will be prioritized by date the order was received and
countries’ stock levels, but multiple shipments may be needed to complete the
order. New orders through GDF may be subject to substantial delay, with
delivery unlikely before the end of 2011. In November, GDF warned of an
anticipated temporary shortage of quality-assured streptomycin, which is used
to treat multidrug-resistant (MDR) TB, and countries were advised to consider
different temporary solutions. Since then, GDF has identified manufacturers that
produce streptomycin according to GDF’s quality assurance policy, but the
production capacity of these producers is limited, and production costs are high.
The shortage was related to quality issues of the active pharmaceutical
ingredient source used by one of the main suppliers of streptomycin, as well as
more stringent quality assurance policies adopted by major donors and
technical agencies. GDF is working with industry in various countries and with
World Health Organization experts. Together, they are working on quality and
safety of drugs to facilitate the inspections and product assessments required
for alternative manufactures to become eligible for supplying GDF drugs. GDF
will maintain contact with countries to collect information on stock levels and
notify them of the status of their streptomycin orders.
3. DOH Turns Over Microscopes for TB Program to 6 Aklan Towns (The
Philippines)
Stop TB Citizen News, http://stoptb.citizen-news.org, January 18, 2011, by Venus
G. Villaneuva PIA News
The Philippine Department of Health recently provided microscopes to six Aklan
towns. The microscopes were received by Aklan Governor Carlito, S. Marques,
from Dr. Ariel Valencia, Regional Director DOH-6, and will be distributed to the
municipalities Lezo, Libacao, Ibajay, Batan, New Washington and Makato. These
microscopes are to be used for implementation of Aklan’s programs to fight TB,
and will be used by medical technologists on duty in rural health units.
4. Nunavut Health Officials to TB: ―Taima‖ (Canada)
NunatsiaqOnline, www.nunatsiaqonline.ca, January 13, 2011, by Chris Windeyer
Nunavut public health officials are launching Taima TB (Stop TB) in Inuktitut, a
combination of public education, social media outreach, and door-to-door
screening and treatment. The project raises awareness through town hall
meetings and social media such as Facebook. Teams will help people with latent
TB infection (LTBI) get treatment. The program will boost screening for TB and
urge people with active TB disease to get treatment. The federal government has
provided an $800,000 grant for Taima TB. Taima TB’s approach has the backing
of high-ranking Nunavut officials. The approach was designed with the past in
mind, when many Inuit were taken south for TB treatment in the 1950s and 60s.
Many died or never returned north, and this resulted in much pain and heartache
for the families.
5. Tuberculosis Confirmed in Two Inmates at Prison in Wilkesboro: Hundreds
Tested (United States)
Winston-Salem Journal, www.journalnow.com, January 12, 2011, by Monte
Mitchell, mmitchell@wsjournal.com
About 238 inmates of Wilkes Correctional Center in North Carolina, 56 staff
members, and some outside contacts have been tested for TB, after the disease
was diagnosed in two inmates. According to Wilkes County health officials, the
first case was diagnosed in early November, and testing and notifications began
immediately. The two patients are being treated in Raleigh, and no additional
cases have been confirmed. Wilkes Correctional Center is a minimum-security
state prison, where inmates live in dormitory-style housing, and many are
eligible for work-release programs. Officials are working to notify any contacts,
but health officials believe the potential for exposure is limited, and no one is at
immediate risk. There was one TB case in Wilkes County in 2009, and there were
two in 2008.
6. Technology for Early Diagnosis of TB to Be Piloted in Pakistan (Pakistan)
The News, www.thenews.com, January 15, 2011, by Shahina Maqbool
In 2011, Pakistan’s National TB Control Program (NTP) will begin using
GeneXpert, a rapid diagnostic test that detects TB and rifampin drug resistance.
A $1 million grant from the US State Department will support the pilot project at
15 sites across Pakistan. GeneXpert, which was endorsed by the World Health
Organization, gives results in less than two hours using untreated sputum. Also,
the NTP has received $173 million from the Global Fund to Fight AIDS, TB, and
Malaria, which will be used over the next five years to prevent MDR TB and
manage 17,000 MDR TB cases. Pakistan reports having approximately 15,000
MDR TB patients per year. The grant will provide food and travel allowances for
TB patients and will enable the NTP to upgrade its laboratories for MDR TB
diagnosis. NTP has engaged the private sector in 60 districts to improve MDR TB
prevention, and has piloted the public-private mix approach at hospitals and
health services in different areas of the country. Free drugs are being provided
to all hospitals working to prevent MDR TB. In addition to the National Reference
Laboratory at the National Institute of Health, four laboratories will be
established in the provinces. Pakistan ranks 8th on the WHO list of tuberculosis
high-burden countries in the world. Each year an estimated 300,000 people in
Pakistan develop TB. The country’s case detection rate has risen from 70
percent to 74 percent, and the treatment success rate from 88 percent to 91
percent in the last two years.
7. Additional TB Unit to Come Up in Bhagalpur (India)
The Times of India, http://timesofindia.indiatimes.com, January 19, 2011, by
Kumar Rajesh
The health department in Bhagalpur, India, plans to add a TB unit to the Bihpur
primary health center, as well as adding infrastructure for examining TB patients
to existing primary health centers. In the last six years, the number of TB
patients has increased, despite the use of DOTS, which is recommended by the
World Health Organization. In 2006, there were 2,613 TB patients; in 2007, 3,876;
in 2008, 3,965; and in 2009, 3,915. In response to the steady rise in TB patients,
the health department has decided to decentralize TB treatment, and determine
the number of patients at the primary health centers in the district based on
sputum results. In addition to the TB unit at Bihpur, laboratories will be opened
in eight primary health centers. These laboratories will assist in early detection
of the disease and provide free antituberculosis drugs to patients. According to
Dr. Madhukar Prasad, District TB Program Officer, the additional TB units and
laboratories will help the health department control the disease by providing
early diagnosis and treatment.
Journal Articles
1. AIDS. 2010 Nov; Volume 24 Suppl 5:S37-44. 'Team up against TB': Promoting
Involvement in Thibela TB, a Trial of Community-Wide Tuberculosis Preventive
Therapy; Grant, A.D., Coetzee, L., Fielding, K.L., Lewis, J.J., et al.
Click here for PubMed abstract: PubMed
This study describes a program of community education and mobilization to
promote uptake in a cluster-randomized trial of TB preventive therapy offered to
all members of intervention clusters. The intervention took place in the gold
mines in South Africa, where TB incidence is extremely high, despite
conventional control measures. All employees in intervention clusters (mine
shaft and associated hostel) were invited to enroll. The main outcome measure
was cumulative enrolment in the study in intervention clusters. Key steps in
communicating information relevant to the study included extensive
consultation with key stakeholders; working with a communication company to
develop a project 'brand'; developing a communication strategy tailored to each
intervention site; and involving actors from a popular television comedy series
to help inform communities about the study. One-to-one communications used
peer educators along with study staff, and participant advisory groups facilitated
two-way communication between study staff and participants. By contrast,
treatment 'buddies' and text messaging to promote adherence proved less
successful. Mean cumulative enrolment in the first four intervention clusters was
61.9%, increasing to 83.0% in the final four clusters. It is concluded that a
tailored communication strategy can facilitate a high level of enrollment in a
community health intervention.
2. AIDS. 2010 Nov; Volume 24 Suppl 5:S19-27. Symptom and Chest Radiographic
Screening for Infectious Tuberculosis Prior to Starting Isoniazid Preventive
Therapy: Yield and Proportion Missed at Screening; Churchyard, G.J., Fielding,
K.L., Lewis, J.J., Chihota, V.N., et al.
Click here for PubMed abstract: PubMed
This study describes the prevalence of and risk factors for TB at screening prior
to isoniazid preventive therapy (IPT), the additional yield of TB using chest
radiography versus symptoms alone, and risk factors for TB missed by
screening. A cross-sectional analysis of a trial of community-wide IPT was
conducted in the South African gold mines. Participants were screened for TB
prior to starting IPT using symptoms (cough >2 weeks, weight loss, night
sweats) and chest radiography. TB suspects had sputum collected for
mycobacterial investigations. Those with a positive smear or culture with no
speciation or culture identified as Mycobacterium tuberculosis were classified as
having probable or definite TB, respectively. Among participants who were
dispensed IPT, the researchers defined a 'missed' case of active TB as one
identified within 90 days of the enrollment screen. Between July 2006 and
December 2008, among 23,286 participants with complete data, the prevalence of
undiagnosed TB [definite (284) and probable (31)] was high (315/23 286; 1.4%).
The addition of chest radiography to symptom screening increased the number
of definite TB cases detected by 2.5-fold (113 to 281 cases). Among 19,609
individuals correctly screened for TB who started IPT and had more than 90 days
of follow-up, only 39 (0.2%) active TB cases were missed. Risk factors for TB
missed by screening included increasing age [adjusted odds ratio (aOR) 1.66/10
year increase, 95% confidence interval (CI) 1.07-2.56], non-South African, in HIV
care (aOR 4.80, 95% CI 1.63-14.1), lower weight (aOR 2.07/10 kg decrease, 95% CI
1.23-3.49) and alcohol use (aOR 2.52, 95% CI 1.31-4.86), which were similar to
risk factors for TB detected by screening. TB screening prior to IPT detects a
substantial burden of TB and misses very few cases. Chest radiography
significantly increased the yield of TB cases detected.
3. Bull World Health Organ. 2010 Dec 1;88(12):937-942. Epub 2010 Sep 29.
Engaging Hospitals to meet Tuberculosis Control Targets in China: Using the
Internet as a Tool to Put Policy into Practice; Wang, L., Liu, X., Huang, F., Hennig,
C., et al.
Click here for PubMed abstract: PubMed
TB services in China are provided through a large network of TB dispensaries.
Even though hospitals are not as well placed to follow recommended standards
of TB care, a significant proportion of people with TB symptoms seek care from
hospitals. In spite of having a policy and mandate in place, the Ministry of Health
had little success in encouraging hospitals to refer suspected TB cases to
dispensaries. Following the epidemic of severe acute respiratory syndrome in
2003, the government set up a nationwide Internet-based communicable
diseases reporting system. This achieved productive collaboration between
hospitals and TB dispensaries. From 2004 to 2007, the percentage of TB
suspects and patients needing referral from hospitals who arrived in TB
dispensaries increased substantially from 58.7% to 77.8% and the contribution of
hospitals to diagnosing sputum smear-positive TB cases doubled from 16.3% to
32.9%. Using the Internet-based reporting system, hospitals in China contributed
to finding about one third of all sputum smear-positive TB cases and helped
meet the global TB control target of detecting 70% of such cases. Based on the
data available from routine surveillance facilitated by this Internet-based system,
this paper details the process and outcomes of strengthening collaboration
between hospitals and TB dispensaries using the Internet as a tool and its
potential application to other country settings.
4. Drugs. 2010 Dec 3; Volume 70, Number 17: 2201-14. doi: 10.2165/11538170-
000000000-00000. Drugs in Development for Tuberculosis; Ginsberg, A.M.
Click here for PubMed abstract: PubMed
TB drug research and development efforts have resurged in the past 10 years to
meet urgent medical needs, but enormous challenges remain. These urgent
needs are largely driven by the current long and arduous multidrug regimens,
which have significant safety, tolerability, and compliance issues; rising and
disturbing rates of multidrug- and extensively drug-resistant TB; the existence of
approximately 2 billion individuals already latently infected with Mycobacterium
tuberculosis, the causative pathogen of TB; and a global TB-HIV co-epidemic.
Stakeholders in TB drug development are moving to enable and streamline
development and registration of novel, multidrug treatment regimens, comprised
of multiple new chemical entities with novel mechanisms of action that do not
demonstrate cross-resistance to current first- and second-line TB drugs. Ideally,
these new regimens will ultimately provide a short, simple treatment suitable for
essentially all TB patients, whether sensitive or resistant to the current anti-TB
agents, whether HIV-infected or HIV-non-infected, and irrespective of patient age.
This article reviews the challenges faced by those trying to develop these novel
regimens and the key agents currently in clinical testing for TB; the latter are
organized for discussion into three categories: (i) novel drugs (TMC207, SQ109,
sudoterb [LL3858]); (ii) present first-line TB drugs being re-evaluated to optimize
their efficacy (rifampicin, rifapentine); and (iii) currently licensed drugs for other
indications and 'next-generation' compounds of the same chemical class being
repurposed for TB (gatifloxacin and moxifloxacin; linezolid, PNU100480 and
AZD5847; metronidazole, OPC-67683 and PA-824).
5. Ethiopian Medical Journal. 2010 Jul; Volume 48, Number 3: 203-10.
Identification of Drug Susceptibility Pattern and Mycobacterial Species in
Sputum Smear Positive Pulmonary Tuberculosis Patients with and without HIV
Co-Infection in North West Ethiopia; Mekonen, M., Abate, E., Aseffa, A., Anagaw,
B., et al.
Click here for PubMed abstract: PubMed
Ethiopia is among the high-burden countries of TB in the world. Since
mycobacterial culture and susceptibility testing are not routinely performed in
Ethiopia, recent data on susceptibility patterns and the mycobacterial species
cultured from sputum smear positive patients are limited. This study determined
first line anti-TB drug susceptibility of Mycobacterium tuberculosis isolates
obtained from consecutive newly diagnosed smear positive pulmonary TB
patients in northwest Ethiopia. A retrospective cross sectional study was
conducted using previously collected sputum samples (n=180) kept at the
referral hospital of the University of Gondar at -20 degrees C. Sputum samples
were cultured on Lowenstein Jensen (LJ) medium. Conventional polymerase
chain reaction (PCR), using RD4 primers to identify the M. tuberculosis complex,
was performed on cultured isolates. Ninety eight (84.4%) of the 116 isolates
identified as M. tuberculosis were tested for their drug susceptibility pattern
using the proportion method. Clinical baseline data including body mass index,
body temperature, clinical symptoms, and erythrocyte sedimentation rate were
obtained. The culture retrieval rate of previously frozen sputum samples was
64.4% (116/180). All the isolated mycobacterial species (n=116) were confirmed
as belonging to the M. tuberculosis complex by PCR. Of 98 isolates for which the
drug susceptibility test was done, 15.3% (15/98) were found to be resistant to one
or more antimycobacterial drugs, and resistance to isoniazid and streptomycin
was most common with 8.2% (8/98) and 6.1% (6/98) respectively. TB patients co
infected with HIV had increased erythrocyte sedimentation rate, higher age, and
lower sputum smear grade than HIV negative TB patients. No mycobacteria other
than M. tuberculosis were detected in sputum smear positive TB-patients.
Although no multi drug resistant strain was observed, relatively high rates of INH
resistance were found in this region. Culture facilities are urgently needed in
regional centers to increase diagnostic sensitivity and monitor developing
trends of drug resistance in Ethiopia.
6. Ethiopian Medical Journal. 2010 Jul; Volume 48, Number 3: 195-202. Quality of
Tuberculosis Care in Six Health Facilities of Afar Region, Ethiopia; Girma, A.,
H/Mariam, D., Deribe, K.
Click here for PubMed abstract: PubMed
Quality TB care plays an important role in the status of TB control, treatment
completion, and adherence. Nonetheless, very little is known about the quality of
TB care in public health facilities in Ethiopia. In this study the researchers
assessed the quality of TB care delivery in Afar Region of Ethiopia. A descriptive
cross sectional health institution based survey with both semi-structured and
structured questionnaires was employed. A mix of complementary techniques
was administered. Data were collected between 5th February and 10th March
2007 from six health institutions. Records were reviewed for 270 patients, exit
interviews were made for 209 patients, six providers were interviewed, and 49
patients were observed. Data were collected by trained nurses and analyzed
using SPSS 11.0 statistical software. The study showed that delivery of
materials, drugs, and supplies for TB control activities were fairly good. Staffing
qualities were poor, and patterns of supervision were weak. A relatively higher
proportion of patients were dissatisfied with the appropriateness and adequacy
of working hours (63.6%) and waiting time (70.3%). Statistically significant
correlation was observed between process quality and output quality (clients'
satisfaction) parameters (p < 0.001). Continued quality improvement mechanisms
to improve the different aspects of the program and adherence to the National
Tuberculosis and Leprosy Control Program guideline could be important
interventions to enhance the quality of care delivery. An expanded community-
based study to better guide quality DOTS program in pastoral communities is
crucial.
7. The European Respiratory Journal. 2010 Dec; Volume 36, Number 6: 1242-
1247. Challenges and Perspectives for Improved Management of
HIV/Mycobacterium tuberculosis Co-Infection; Sester, M., Giehl, C., McNerney,
R., Kampmann, B., et al.
Click here for PubMed abstract: PubMed
HIV and Mycobacterium tuberculosis (MTB) are two widespread and highly
successful microbes whose synergy in pathogenesis has created a significant
threat for human health globally. In acknowledgement of this fact, the European
Union (EU) has funded a multinational support action, the European Network for
global cooperation in the field of AIDS and TB (EUCO-Net), which brings together
experts from Europe and those regions that bear the highest burden of HIV/MTB
co-infection. In this article, the authors summarize the main outcome of the
EUCO-Net project derived from an expert group meeting that took place in
Stellenbosch (South Africa) (AIDS/TB Workshop on Research Challenges and
Opportunities for Future Collaboration) and the subsequent discussions, and
propose priority areas for research and concerted actions that will have impact
on future EU calls.
8. Future Microbiology. 2010 Oct; Volume 5:1581-97. Protein Export Systems of
Mycobacterium tuberculosis: Novel Targets for Drug Development? Feltcher,
M.E., Sullivan, J.T., Braunstein, M.
Click here for PubMed abstract: PubMed
Protein export is essential in all bacteria and many bacterial pathogens depend
on specialized protein export systems for virulence. In Mycobacterium
tuberculosis, the etiological agent of the disease TB, the conserved general
secretion (Sec) and twin-arginine translocation (Tat) pathways perform the bulk
of protein export and are both essential. M. tuberculosis also has specialized
export pathways that transport specific subsets of proteins. One such pathway
is the accessory SecA2 system, which is important for M. tuberculosis virulence.
There are also specialized ESX export systems that function in virulence (ESX-1)
or essential physiologic processes (ESX-3). The increasing prevalence of drug-
resistant M. tuberculosis strains makes the development of novel drugs for TB
an urgent priority. In this article, the researchers discuss their current
understanding of the protein export systems of M. tuberculosis and consider the
potential of these pathways to be novel targets for TB drugs.
9. The Indian Journal of Tuberculosis. 2010 Apr; Volume 57, Number 2: 75-9. Can
Cord Formation in BACTEC MGIT 960 Medium be Used as a Presumptive Method
for Identification of M. tuberculosis Complex? Kadam, M., Govekar, A., Shenai,
S., Sadani, M., et al.
Click here for PubMed abstract: PubMed
Serpentine cord formation in BACTEC MGIT 960 medium was evaluated as a
rapid method for the presumptive identification of M. tuberculosis complex
(MTBC). A total of 2,527 samples were processed for AFB culture using MGIT 960
TB system over a period of three months. AFB smears were prepared from 1000
MGIT tubes flagged positive by the MGIT instrument and stained by ZN method
to examine presence or absence of serpentine cording. The cord formation was
compared with PNBA [p-nitro benzoic acid] test on MGIT system and all
controversial cases were further evaluated by NAP [p-nitro-a-acetylamino-
phydroxypropiophenone] test on BACTEC 460 TB system. Of the 1,000 culture
positives, 904 (90.4%) were identified as mycobacteria, of which 869 (96%)
showed cording by smear microscopy. One (0.1%) was identified as nocardia. In
the remaining 95 (9.5%) cases, primary smear made from MGIT vial was negative.
Of 869 cultures showing serpentine cord formation, 842 were confirmed as
MTBC and 27 as NTM by PNBA assay on MGIT 960 TB system. The sensitivity,
specificity, positive and negative predictive values are found to be 99.6%, 54%,
96%, and 91% respectively. An average detection time for PNBA assay was
found to be eight days whereas cording results were available on the same day
of culture positivity. Though highly sensitive it is not very specific and hence
cannot be the only test for presumptive diagnosis of MTBC.
10. The Indian Journal of Tuberculosis. 2010 Apr; Volume 57, Number 2: 67-74.
Detection of Circulating Free and Immune-Complexed Antigen in Pulmonary
Tuberculosis Using Cocktail of Antibodies to Mycobacterium tuberculosis
Excretory Secretory Antigens by Peroxidase Enzyme Immunoassay; Majumdar,
A., Kamble, P.D., Harinath, B.C.
Click here for PubMed abstract: PubMed
Decreased sensitivity has been a limiting factor of antigen assay for detection of
TB. Assay of more than one antigen may improve sensitivity of an assay. To
develop a simple, rapid and less-expensive serodiagnostic method compared to
culture method for Pulmonary Tuberculosis. A cocktail of affinity purified
antibodies against Mycobacterium tuberculosis H37Ra antigens (SEVA TB ES-
31, ES-43 and EST-6) was explored for detection of circulating free and immune-
complexed (IC) cocktail antigen by microtiter plate peroxidase sandwich ELISA.
The assay was evaluated in 27 clinical sera of sputum acid fast bacilli (AFB)
positive and 10 AFB negative, but anti-tuberculosis therapy responded to
pulmonary TB patients and 20 normal sera as controls. Assay of cocktail antigen
showed marginal improvement in sensitivity compared to assay of ES-31 antigen
alone. The assay for circulating free cocktail antigen showed a sensitivity of
77.7% for AFB positive cases and 70% for AFB negative cases compared to
assay of ES-31 antigen with sensitivity of 74% and 70% respectively. The assay
for IC-cocktail antigen showed sensitivity of 77.7% for AFB positive and 80% for
AFB negative cases compared to assay of ICES-31 antigen with sensitivity of
77% and 70% respectively. Specificity of antigen assay was found to be 90%.
Detection of IC-antigen as adjunct assay improved the sensitivity of detection in
AFB-ve but ATT responded cases. Peroxidase enzyme immunoassay of cocktail
antigen showed a sensitivity of detection of 0.25 microg/ml and levels of free and
IC cocktail antigens were 1.70 +/- 1.04 and 1.13 +/- 0.047 microg/ml in AFB
positive patients' sera. Peroxidase enzyme immunoassay for circulating antigen
was found to be a useful serodiagnostic assay and in particular in AFB-ve cases
responding to ATT.
11. Japanese Journal of Infectious Diseases. 2010 Nov; Volume 63, Number 6:
433-6. Is the T-Cell-Based Interferon-Gamma Releasing Assay Feasible for
Diagnosis of Latent Tuberculosis Infection in an Intermediate Tuberculosis-
Burden Country? Gorek Dilektasli, A., Erdem, E., Durukan, E., Oner Eyüboğlu, F.
Click here for PubMed abstract: PubMed
The diagnosis of active and latent TB infection (LTBI) remains a challenge,
especially in light of the fact that the tuberculin skin test (TST), which has been
used to diagnose LTBI for over a century, has many well-known drawbacks. This
study compared the diagnostic performance of the T-cell-based interferon-
gamma releasing assay (IGRA) T-SPOT.TB with the TST for the diagnosis of LTBI
in an intermediate TB-burden country with high BCG coverage. For this purpose,
a total of 91 participants, including culture-confirmed TB patients, healthy
contacts known to have been exposed to Mycobacterium tuberculosis, and
healthy volunteers, selected from a BCG-vaccinated population were recruited.
The sensitivities of the T-SPOT.TB and TST were 79.3 and 25.8%, and the
specificities were 75.9 and 56.7%, respectively. The negative- and positive-
predictive values for T-SPOT.TB and TST were 78.6 and 76.7% and 42.5 and
38.1%, respectively. The diagnostic performance of the TST in LTBI diagnosis is
therefore severely diminished in BCG-vaccinated populations, with the
sensitivity and specificity of the T-SPOT.TB assay being markedly higher. IGRAs
have been reported to have higher diagnostic sensitivity and specificity in low
TB-incidence settings than those seen here. Further larger scale studies in high
and intermediate TB-incidence settings are therefore warranted.
12. Journal of Acquired Immune Deficiency Syndromes. 2010 Dec 1; Volume 55,
Number 4: 446-50. Causes of Early Mortality in HIV-Infected TB Suspects in an
East African Referral Hospital; Kyeyune, R., den Boon, S., Cattamanchi, A.,
Davis, J.L., et al.
Click here for PubMed abstract: PubMed
Respiratory infections are a leading cause of death in Africa, especially among
HIV-infected patients. Data on the etiology of fatal respiratory diseases are
largely based on autopsy studies. The researchers evaluated causes of
pneumonia associated with early mortality among hospitalized HIV-infected
patients in Kampala, Uganda. Prospective cohort study of HIV-infected patients
admitted to Mulago Hospital, Kampala, with at least 2 weeks of cough.
Consecutively enrolled patients with negative Ziehl Neelsen sputum smears for
acid-fast bacilli underwent bronchoscopy with bronchoalveolar lavage and
examination for mycobacteria (smear, solid culture), Pneumocystis jirovecii
(Giemsa stain), and fungi (KOH mount, India ink stain, Sabouraud culture). Early
mortality was defined as death before the 2-month follow-up visit. Follow-up
data were available for 353 (87%) of 407 patients enrolled. Of participants with
follow-up data, 112 (32%) died within 2 months. Among patients with early
mortality, a diagnosis was confirmed in 74 (66%), including TB (56%),
cryptococcal pneumonia (1%), Pneumocystis pneumonia (3%), pulmonary
Kaposi sarcoma (4%), and pneumonia caused by 2 or more disease processes
(3%). Mortality in HIV-infected TB suspects is high, with TB associated with the
largest proportion of deaths. A significant proportion of patients die without a
confirmed diagnosis.
13. The Journal of the Egyptian Public Health Association. 2010; Volume 85,
Number 1-2: 61-71. Prevalence of Latent TB among Health Care Workers in Four
Major Tertiary Care Hospitals in Riyadh, Saudi Arabia; Abbas, M.A., Alhamdan,
N.A., Fiala, L.A., Elenezy, A.K., et al.
Click here for PubMed abstract: PubMed
TB infection represents a global health problem and a great risk to health care
workers (HCWs). Identifying individuals, particularly HCWs with latent TB
infection (LTBI) will support TB control through chemoprophylaxis and prevent
cross-infection. This study identified prevalence of LTBI among a group of two-
year new hires of HCWs in 4 major tertiary care hospitals in Riyadh, Saudi
Arabia. 2,650 recently-hired (2-years) HCWs were screened for LTBI using the
Tuberculin Skin Test (TST). Data were collected from January 2008 to December
2009. Induration due to TST equal to or more than 10 mm. within 48-72 hours was
considered positive. The results of TST were correlated with other variables such
as age group, gender, job category, country of origin. As an overall rate,
291(11%) out of 2,650 were positive for TST, with the highest significant positive
rates among physicians (14.9%) and nurses (12.9%) compared to students as a
reference group. No statistically significant difference was detected between
both sexes. The highest significant positive TST rates were found among HCWs
in the age group of 50 years and older (32.6%) compared to 10-19 years age
group as a reference group, and among HCWs coming from sub-Saharan
countries (61.1%) compared to Saudi HCWs with the lowest positive rates (5%)
as a reference group. LTBI is prevalent among newly-hired HCWs in Riyadh
tertiary hospitals. Standard programs for detection and treatment of LTBI should
be encouraged.
14. Journal of Microbiology, Immunology, and Infection. 2010 Oct; Volume 43,
Number 5: 395-400. Abdominal Tuberculosis in Adult: 10-year Experience in a
Teaching Hospital in Central Taiwan; Chou, C.H., Ho, M.W., Ho, C.M., Lin, P.C., et
al.
Click here for PubMed abstract: PubMed
TB is an important communicable disease worldwide. The clinical presentation
of abdominal TB often mimics various gastrointestinal disorders and may delay
accurate diagnosis. In this study, the researchers conducted a 10-year
retrospective study to investigate the clinical manifestations, treatment
responses, and outcomes of abdominal TB. This retrospective study recruited
patients presenting between January 1998 and December 2007; all patients ≥ 18
years of age with a diagnosis of abdominal TB were enrolled. Patient charts were
thoroughly reviewed and clinical specimens were processed in the laboratory
using the BBL MycoPrep System and BACTEC MGIT 960 Mycobacterial
Detection System. Mycobacterium tuberculosis complex was confirmed by acid
fast stain and the BD ProbeTec ET System. During the study period, 34 patients
were diagnosed with abdominal TB. The mean age was 55+18 years. Fourteen
patients (41%) had no risk factors; however, 20 patients (59%) had at least one
risk factor. Abdominal pain (94.1%), abdominal fullness (91.2%), anorexia
(88.2%), and ascites (76.5%) were the most common presenting symptoms. The
peritoneum (88%) was the most commonly involved site. Patients with risk
factors such as liver cirrhosis, end-stage renal disease, and diabetes mellitus
had a higher positive rate of acid-fast stain and mycobacterial culture from
abdominal specimens (p = 0.02 and 0.05, respectively). The crude mortality rate
was 9% and the attributed mortality rate was 3%. In an endemic area like Taiwan,
regardless of whether a patient has risk factors for TB, abdominal TB should be
seriously considered as a differential diagnosis when a patient presents with
gastrointestinal symptoms and unexplained ascites.
15. Journal of Microbiology, Immunology, and Infection. 2010 Oct; Volume 43,
Number 5: 386-94. Does Radiographic Evidence of Prior Pulmonary Tubercular
Infection Influence the Choice of Empiric Antibiotics for Community-Acquired
Pneumonia in a Tuberculosis-Endemic Area? Jeng, Y.Y., Lin, Y.T., Huang, L.J.,
Chen, T.L., et al.
Click here for PubMed abstract: PubMed
Recent medical literature suggests that use of fluoroquinolones (FQs) might be
associated with the delayed diagnosis of pulmonary TB. This study assessed the
impact of radiographic evidence of prior pulmonary TB infection on empiric
antibiotic choice in cases of community-acquired pneumonia (CAP), as well as
the effect of antibiotic regimens on clinical outcome. A total of 280 patients with
CAP between 1 May and 31 December 2007 were included in the study and their
medical records were retrospectively reviewed. Patients were divided into two
groups: those receiving FQs (FQ group) or those receiving β-lactam-based
regimens (β-lactam group). Their demographic data, underlying diseases, clinical
features, diseases severity, and outcomes were compared. Radiographic
evidence of a previous pulmonary TB infection (odds ratio = 3.507, 95%
confidence interval = 1.422-8.645; p = 0.006) was an independent factor
associated with β-lactam-based regimens. Patients with a modified pneumonia
severity index (mPSI) category V were more likely to receive FQ therapy (odds
ratio = 2.53, 95% confidence interval = 1.140-5.615; p = 0.022). Of the patients
with mPSI category V, the 14-day mortality rate of those in the β-lactam group
was significantly lower than that of those in the FQ group (0%vs. 23%,
respectively; p = 0.044). Radiographic evidence of a previous pulmonary TB
infection and a lower mPSI score increases the probability of the selection of a β-
lactam-based regimen for the treatment of CAP.
Job Announcements
All job announcements will be posted for two months. Please notify us if a job is
filled before the end of the two-month posting period, and we will remove the job
announcement. Thank you.
1. Stop TB Advocacy Officer - Washington (DC)-based NEW
Sponsors: RESULTS Educational Fund; Stop TB Partnership Secretariat
Location: Washington, DC
The Stop TB Partnership (TBP) Coordinating Board endorsed the enhancement
of the TBP’s advocacy influence, including strategy, coordination,
communications, support, and leadership engagement. The Board mandated
TBP to clearly define the responsibilities and the budget implications of a
Washington-based position, and to open discussions with partners regarding the
creation of such a position within their organization.
These discussions have resulted in the proposed grant to RESULTS Educational
Fund (REF) as partial funding for a Stop TB Advocacy Officer—additional to the
staff currently working at REF on TB advocacy—to be hosted at their offices in
Washington, DC. The grant will be for an initial period of 1 year. Subject to
results achieved and availability of funds, a similar arrangement may be
considered subsequently.
For more information, including the objectives of this position, duties,
qualifications, experience, and skills, interested applicants should e-mail
action_jobs@results.org. Applications will be reviewed on a rolling basis, so
early submission is recommended. No phone calls please, qualified candidates
will be contacted.
2. Training and Consultation Specialist
Sponsor: New Jersey Medical School Global Tuberculosis Institute
Job Number: 10NS963549
Location: Newark, New Jersey
The New Jersey Medical School Global TB Institute is currently accepting
applications for a Training and Consultation Specialist.
The primary purpose of the Training and Consultation Specialist position is to
develop, implement, and evaluate educational programs and materials related to
TB to meet the needs of health care professionals and TB patients. These
activities will be consistent with the goals and objectives of the CDC funded
Regional Training and Medical Consultation Centers initiative, or with other
national or international TB control projects. These programs may include
training courses, lectures, symposia, preceptorships, and enduring materials,
including curricula and self study materials. Responsibilities will include
developing and implementing training courses for TB Program staff and
developing patient and provider educational materials for use in domestic and
international settings. Previous experience in international TB training and
education is desired.
More information and an online application are available at:
http://umdnj.hodesiq.com/job_detail.asp?JobID=2194623&user_id=
3. Director, Tuberculosis Programs (Tracking code 4307)
Sponsor: PATH
Location: Hanoi, Vietnam
PATH seeks a dynamic and experienced public health professional to lead and
manage its increasingly large and complex portfolio of TB Control projects;
represent PATH to donors, partners, and government agencies;, and serve as a
member of PATH Vietnam’s senior management team.
With support from the Global Fund to Fight AIDS, TB and Malaria and the United
States Agency for International Development (USAID) and in partnership with the
National TB Program, PATH is expanding its TB control program in Vietnam with
two major initiatives. The Global Fund project is designed to scale up technical
components and partnerships to increase TB control impact while the USAID-
funded project will reduce diagnostic delays, increase case detection, and
improve adherence to TB treatment through strengthened stakeholder
involvement in TB control activities at the district, provincial, and national levels.
The Global Fund project will implement a public-private partnership model for TB
case detection, and both projects will strengthen capacity for advocacy,
communication, and social mobilization toward the goal of eliminating TB as a
public health threat. Reporting to the Country Program Leader, the incumbent
will oversee a combined budget of nearly nine million USD and 24 staff, including
six direct reports.
Specific responsibilities include:
(1) Project Leadership, Management and Oversight:
- Assume strategic leadership and direct planning, implementation, and
management for Global Fund project and oversight for USAID TB project,
including strategic support for program objectives, key interventions, and
evaluation strategies.
- Liaise with Global TB program staff integrating TB work in Vietnam with overall
PATH strategy for TB Control.
- Oversee rapid start-up of project activities for each initiative: hiring staff and
initiating and building relationships with key stakeholders.
- Develop and coordinate the annual budgeting process for each project; ensure
prudent management of project funds; coordinate each project’s accounting,
monitoring, and reporting systems, including establishing internal control
systems in accordance with PATH’s standard operating procedures.
- Represent PATH to donors, partners, and government agencies, and oversee
coordination activities with the National TB Program.
- Support the Country Program Leader in managing all donor-related compliance
matters, ensuring that project teams achieve project goals and objectives
according to donor expectations and within approved project budgets.
- Work with staff to develop strategy for each project and identify
issues/challenges for effective implementation of work plan activities.
- Oversee preparation of required reports to Headquarters and donors.
- Maintain updated technical knowledge in TB and related public health topics to
be able to provide vision and input to strategy development and technical
assistance to project staff.
(2) PATH Representation:
- On delegation, serve as the PATH representative to donors, collaboration
institutions, other potential clients and partners, and the press.
- Serve as a member of the senior management team contributing to strategic
policy and program directions and decisions.
- Represent PATH on national working groups and task forces as appropriate
and maintain contacts with other organizations engaged in TB control activities.
- Identify and participate in new business opportunities and activities for PATH
including proposal writing.
If interested, forward resume to Sue Wallace. E-mail swallace@path.org, or
apply online at http://www.path.org.
Upcoming Conferences, Trainings, and Other Events
Find up-to-date information on TB-related conferences, US training
opportunities, and other events at the DTBE Monthly Calendar.
1. TB Cohort Review NEW
Sponsor: Heartland National TB Center
Dates: February 24, 2011
Location: San Antonio, Texas
Registration deadline: February 18, 2011
The goal of this training is to introduce health care workers to the TB Cohort
Review process through CDC guidelines, case examples, and group exercises.
Using interactive lectures as well as case presentations and group exercises,
participants will be able to list elements of a cohort review, identify key
participants and their role, prepare for and conduct a practice cohort review,
demonstrate an actual cohort review, and analyze the data to understand
outcomes and programmatic follow-up.
There is no charge to attend this workshop, but pre-registration is mandatory.
Space is limited to 25 participants. Register at
http://www.heartlandntbc.org/training.asp . Continuing education credits are
available.
For more information, contact Jessica Quintero. E-mail
Jessica.quintero@uthct.edu;
telephone (210) 531-4568; or access the Web site at
http://www.heartlandntbc.org/training/brochure_san_antonio_TX_24_feb_2011.p
df.
2. TB in Corrections NEW
Sponsor: Heartland National TB Center
Date: March 24, 2011
Location: Phoenix, Arizona
Registration deadline: March 10, 2011
This course is designed for the registered nurse and other health care
professionals who are tasked with the management of TB in correctional
facilities at the local, state, and federal level. The goal of this training is to
enhance the knowledge of TB prevention and control measures within the
correctional setting.
There is no charge to attend this workshop, but pre-registration is mandatory.
Space is limited to 35 participants. Register at
http://www.heartlandntbc.org/training.asp . Continuing education credits are
available.
For more information, contact Jessica Quintero. E-mail
Jessica.quintero@uthct.edu;
telephone (210) 531-4568; or access the Web site at
http://www.heartlandntbc.org/training/brochure_phoenix_az_24_mar_2011.pdf.
3. Strategic Planning and Innovation NEW
Dates: August 15 – 20, 2011
Sponsor: International Union Against Tuberculosis and Lung Disease (The
Union)
Location: Singapore
Application deadline: July 10, 2011
Leading teams that work within critical areas of health care is a considerable
challenge for any national TB program manager who is expected to develop and
adhere to strategies for a country’s health projects. Participants in this course
will learn to foresee potential difficulties and confidently meet them by
developing successful health program strategies. This course will help them to
become stronger leaders within their health organizations The course focuses
on creating a learning organization that has the capacity to identify key issues
blocking organizational progress – whether operational, strategic, or policy-
related. Key topics the course addresses: (1) learning how to lead a participative
strategic planning activity within your TB program, (2) developing a focused
approach to strategy implementation, (3) expanding your operations by
creatively using simple tools and techniques, and (4) strengthening health
systems through exploration of innovative and creative practices.
Late applications accepted on a space-available basis. To register, e-mail
imdp@theunion.org.
For more information, e-mail technical-courses@theunion.org; or visit the Web
site at http://www.union-imdp.org/courses/strategic-planning-innovation.
4. Targeted Testing and Treatment of Latent TB Infection: An Online Presentation
(60 minutes)
Sponsor: The Francis J. Curry National Tuberculosis Center
This slide presentation is presented by L. Masae Kawamura, M.D., TB Controller
of the San Francisco Department of Public Health and co-principal investigator
of the Francis J. Curry National TB Center/UCSF. Dr. Kawamura explores the
diagnosis and treatment of LTBI, including: the rationale for TB screening and
what is meant by "targeted testing," risk factors for TB, the tuberculin skin test
and new interferon gamma release assays (IGRAs), current LTBI treatment
guidelines, and how to counsel and motivate patients. This slide presentation
with streaming audio provides information on how to effectively target test for
TB as well as how to treat latent TB infection (LTBI). A question and answer
guide, a printable PowerPoint slide file, and other useful resources are also
included as supplemental materials.
For more information, visit http://www.nationaltbcenter.ucsf.edu/testing_ltbi/ .
5. Practical Solutions for TB Infection Control: Infectiousness and Isolation
Sponsor: Francis J. Curry National Tuberculosis Center
Location: Online Course
Length: 60 minutes
This 60-minute Flash presentation with streaming audio provides information on
how to determine whether a TB patient is infectious and demonstrates practical
ways to prevent TB transmission in the clinic, in transit, and in the patient's
home. Throughout the training, interactive questions allow participants to test
and apply what has been learned. At the end of the presentation, there is a list of
additional resources that includes links to further written information as well as
links to the Regional Training and Medical Consultation Centers (RTMCCs).
For further assistance, contact Francis J. Curry National Tuberculosis Center. E-
mail tbcenter@nationaltbcenter.ucsf.edu; telephone (415) 502-4600; or fax (415)
502-4620.
For a course description, visit http://www.nationaltbcenter.ucsf.edu/tbicweb/ .
6. Medical Management of Tuberculosis: An Online Presentation
Sponsor: Francis J. Curry National Tuberculosis Center
Length: 30 minutes
Credit: 0.5 contact hour CME/CNE
This slide presentation with streaming audio will provide information on how to
manage treatment of TB. A question and answer guide, a printable PowerPoint
slide file, and other useful resources are also included as supplemental reading
materials. This 30-minute lecture, conducted by Dr. Karen Smith, covers the
general principles of TB treatment, the drugs used to cure TB, alternative
regimens, monitoring, and potential adverse reactions to therapy. It targets
audiences of clinicians and health care professionals.
For a course description or to receive continuing medical education (CME) or
continuing nursing education (CNE) contact hours, please visit
http://www.nationaltbcenter.edu/med_mgmt/ .
7. Legal Interventions in TB Control: A Web-Based Seminar
Sponsor: New Jersey Medical School Global Tuberculosis Institute
Location: Web-Based Seminar
This web-based seminar, presented by the Global TB Institute, was originally
held on September 11, 2007 and explored successful and innovative approaches
to implementing legal interventions in TB control programs in the US. Experts
shared legal and ethical considerations, as well as hands-on experiences,
practical steps, and legal tools that can be used to improve outcomes of case
management, treatment outcomes, and contact investigations. Points were
illustrated using lectures and case presentations
Please follow the link below to view this web-based seminar:
http://www.umdnj.edu/globaltb/audioarchives/legal.htm .
8. Arresting TB: Best Practices for Controlling TB in Corrections
Sponsor: Southeastern National Tuberculosis Center (SNTC)
Date: January 27, 2011
Location: Forsyth, Georgia
This course highlights best practices for recognizing and controlling TB in
correctional settings and is designed to enhance communication and
collaboration between the local health department and correctional facility staff.
Presented in an interactive case-based lecture format, attendees join in group
discussions and actively participate in exercises designed to foster skills for
managing TB in correctional settings.
Enrollment is limited to 50 participants from the southeastern region.
Registration is free; online pre-registration is required by January 15, 2011.
Continuing education credits are available.
For more information, contact the SNTC. E-mail Ellen.murray@medicine.ufl.edu;
phone (352) 273-9385 or toll free (888) 265-7682; fax (352) 273-9275; or access the
Web site at http://sntc.medicine.ufl.edu/Training.aspx?Id=9242.
9. Webinar: Understanding Mycobacterium bovis
Sponsor: Heartland National TB Center
Date: February 2, 2011
Location: Nationwide, US
Registration deadline: January 31, 2011
This webinar will describe the epidemiologic risk factors and transmission of
Mycobacterium bovis, discuss the differences between Mycobacterium bovis
and Mycobacterium tuberculosis, and identify case management best practices
during treatment of Mycobacterium bovis.
Participants from the Heartland region will be given priority registration.
Continuing education credits are available.
For more information contact the Heartland National TB Center, Email:
Jessica.quintero@uthct.edu; Phone: (800)839-5864; or download the brochure at:
http://www.heartlandntbc.org/training/webinars/20110202/brochure.pdf.
10. Best Practices in TB Control #3: TB Cohort Review in Action: Putting It All
Together
Sponsor: NJMS Global Tuberculosis Institute
Date: February 10, 2011
Location: Nationwide, USA
This web-based seminar will present the entire picture of a cohort review from
start to finish. The format features a simulated cohort review session including
case presentations, feedback, and comments by a program director and medical
reviewer; analysis and summary of outcomes by an epidemiologist; and plans
for each person to follow up on the findings. Presenters are experienced
practitioners from programs in Columbus OH, Philadelphia PA, Washington DC,
and Washington State.
Please register online at:
https://www323.livemeeting.com/lrs/8001122164/Registration.aspx?pageName=q
hn3cwj8q27qnt1s . There is no limit to the number of participants at one location
viewing from one room and computer. However, each site must identify a contact
person to receive conference information, submit the sign-in sheet, and share
the link to the online conference evaluation after the seminar.
Contact: For more information contact Bill Bower, E-mail: blb3@columbia.edu;
Phone: (646) 448-0945; or access the Web site:
http://www.umdnj.edu/globaltb/courses/brochures/2011/cohortreview3.html .
11. Management, Finance and Logistics
Sponsor: International Union Against Tuberculosis and Lung Disease (The
Union)
Dates: February 14 – 26, 2011
Location: Bangkok, Thailand
This course will cover the basics of managing a national health program.
Participants in this course will build financial comprehension, learn how to
communicate more effectively, practice multi-party negotiation, and develop
fundamental budgeting skills. Key topics of the course address: Learning to
develop and understand budgets, Working with financial concepts in order to
make more confident decisions in health projects, Improving procurement of
drug supplies and logistics management through quality assurance and supply-
chain management, and Assessing leadership strengths and building managerial
skills. Combining practical exercises, in-class discussions, presentations, and
lectures, participants will gain a greater understanding of proven and effective
management methods and how they can be directly applied to public health.
This course is also offered in French. Continuing education credits are
available.
For more information, Email: technical-courses@theunion.org; or visit the Web
site: http://www.union-imdp.org/courses/management-finance-logistics .
12. Tuberculosis Clinical Intensive
Sponsor: The Francis J. Curry National Tuberculosis Center (CNTC)
Dates: February 15 – 17, 2011
Location: San Francisco, California
This three-day course is designed for physicians and other licensed medical
professionals who diagnose and treat TB. The course will cover: diagnosis,
management, and treatment of active TB and latent TB infection; TB
transmission and pathogenesis; pediatric TB; drug-resistant TB; TB and HIV
coinfection; and more.
Enrollment is limited and pre-registration is required. There is no fee for this
course. Continuing education credits are available.
For a complete course description and application information, visit:
http://www.nationaltbcenter.ucsf.edu/training/tb_clinical_intensive.cfm.
13. 15th Annual Conference of the Union - North American Region (IUATLD-NAR)
Sponsor: British Columbia Lung Association; International Union Against TB
and Lung Disease (IUATLD) - North American Region
Dates: February 24 – 26, 2011
Location: Vancouver, BC, Canada
This year's theme, "Engaging Vulnerable Populations: Tools and Strategies to
Halt TB," highlights the crucial importance of developing effective partnerships
with those most impacted by TB. The keynote speakers are both internationally
recognized experts in their fields. Dr. Anthony Harries, the George Comstock
lecturer, and Sharon Venne, Beyond TB lecturer, will open the conference by
addressing two global populations who have been the most impacted by TB.
Plenary sessions will focus on several of the region's most at risk for TB,
including indigenous, migrant and immigrant populations, and those affected by
diabetes.
Registration fee (Canadian $): Physicians/PhDs: $500/Non-member,
$450/Member; Nurses and Allied Health Care professionals: $450/Non-member,
$400/Member; Students/Fellows: $250/Non-Member. Continuing education
credits are available.
For more information, contact Menn Biagtan, MD, MPH, British Columbia Lung
Association. E-mail biagtan@bc.lung.ca; phone (604) 731-5864; fax (604) 731-
5810; or access the Web site at
http://www.bc.lung.ca/association_and_services/union.html .
14. TB Case Management and Contact Investigation Intensive
Sponsor: Francis J. Curry National Tuberculosis Center
Dates: March 15 – 18, 2011
Location: San Francisco, California
This course is intended for physicians, nurses, and other licensed medical care
providers who manage patients with TB or who are at risk for TB. Topics covered
include: Epidemiology of TB; Fundamentals of TB case management;
Completion of care; TB contact investigation; The role of the laboratory; Medical
management of TB; Quality assurance in TB control programs; Targeted testing
for TB; Treatment of latent TB infection (LTBI); Culture, community, and TB care;
Working with special populations; and Interviewing skills.
There is no fee for this course. Enrollment is limited, and pre-registration is
required.
For more information, contact Jennifer Kanouse, Program Manager. E-mail
tbcmci@nationaltbcenter.ucsf.edu; phone (415) 502-2712; or access the Web site
at
http://www.nationaltbcenter.ucsf.edu/training/tbcmcimar11.cfm.
15. Mass Media and Communications
Sponsor: International Union Against Tuberculosis and Lung Disease (The
Union)
Dates: March 21 – 25, 2011
Location: Singapore
Application deadline: February 21, 2011
Communication exchange has never been so easily accessible and so critical to
the success of a national health program. Gain a greater understanding of how
effective communications strategies can help promote TB and HIV programs and
further disseminate important health messages to the public. During this course
participants will receive training on how to write a professional press release,
develop useful promotional tools, conduct media outreach, and discover how to
build positive public awareness around an organization’s work. Learning directly
from experts working in mass communications, participants will engage in class
exercises, discussions, and real-life simulations that demonstrate how skillful
use of the media and communications can propel any health program to
excellence.
To register or receive more information, email imdp@theunion.org or visit
http://www.union-imdp.org/courses/mass-media-communications . Late
applications accepted on a space-available basis.
16. Critical Care and Pulmonary Medicine: An Update and Review
Sponsor: American Medical Seminars, Inc.
Dates: March 28 – April 1, 2011
Location: Sarasota, Florida
Following this course, the participant should be able to assess the common
presentation and patient complaints for the various pulmonary disorders
described; implement a diagnostic work-up appropriate for each presented
disorder, considering a practical and cost-effective approach; employ a cost-
effective method of treatment, follow-up, and long-term care when indicated.
This activity is expected to result in improved competence in making an
appropriate diagnosis and providing effective treatment and referral or follow-up
care with the overall goal of improving patient outcomes. The emphasis will be
on aligning physician behavior with current guidelines and evidence-based
medicine, as indicated within each topic’s specific objectives, with a focus on
diagnosis, treatment, and when to refer.
To receive regular registration rate, fees must be received or postmarked at least
30 days prior to program start date. Registration fee: Regular - $745/Physician;
$645/Non Physician; Late - $795/Physician; $695/Non Physician. Continuing
education credits are available.
For more information contact the American Medical Seminars, Inc., E-Mail:
mail@ams4cme.com; Phone: (941) 388-1766; Toll Free: (866) ams4cme (866-267-
4263); Fax: (941) 365-7073; or access the Web site:
http://www.ams4cme.com/www/LiveSeminars/SEMLA-2520110328.aspx .
17. The Denver TB Course
Sponsor: National Jewish Health
Dates: April 13 – 16, 2011
Location: Denver, Colorado
The purpose of this course is to present knowledge about the management of TB
to general internists, public health workers, infectious diseases and chest
specialists, registered nurses, and other healthcare providers who will be
responsible for the management and care of patients with TB. This event
includes the following course highlights: Transmission and pathogenesis of
adult and pediatric TB; MDR TB and XDR TB; Screening for and treatment of
latent TB infection; Factors influencing infections of TB; Planning TB control
programs with particular emphasis on organization of outpatient chemotherapy;
TB and HIV co-infection; and Mycobacteriology Laboratory Tour.
Continuing education credits are available.
For more information contact Nicole Austin Ross, National Jewish Health, E-
mail: rossn@njhealth.org;
Phone: (303) 398-1110; Fax: (303) 270-2239; or access the Web site:
http://www.njhealth.org/TBCourse.
18. Influencing, Networking and Collaboration
Sponsor: International Union Against Tuberculosis and Lung Disease (The
Union)
Dates: April 25 – 30, 2011
Location: Singapore
Application deadline: March 25, 2011
Creating partnerships and networks is an important element to the success of a
TB program. Participants in this course will learn how relationship building and
developing strong partnerships can boost health program results. The course
will address the following key topics: Creating empowered teams and moving
away from the command and control structure, facilitating large stakeholders
meeting and managing conflict, negotiating and partnering with stakeholders
within health programs, and building consensus within large groups of distinct
and diverse personalities.
Application deadline: March 25, 2011. Late applications accepted on a space-
available basis. To register, email imdp@theunion.org .
For more information, Email: technical-courses@theunion.org; or visit the Web
site: http://www.union-imdp.org/courses/influencing-networking-collaboration .
19. Leading Management Teams
Sponsor: International Union Against Tuberculosis and Lung Disease (The
Union)
Dates: June 27 – July 9, 2011
Location: Bangkok, Thailand
Application deadline: May 25, 2011
Bringing measurable changes within a TB program requires a comprehensive
approach to performance management. Participants in this course will learn how
to more effectively guide groups of personnel through advanced management
training by examining their own leadership styles. Key topics the course
addresses include: (1) Creating measurable results in a TB program through
long-term planning; (2) Leading changes in a health organization that build
greater staff commitment, competence, and confidence; (3) Achieving higher
success rates through enhanced team performance; and (4) Developing team
members through coaching and mentoring.
Late applications accepted on a space-available basis. To register, E-mail
imdp@theunion.org.
For more information, E-mail: technical-courses@theunion.org; or visit the Web
site: http://www.union-imdp.org/courses/leading-management-teams.
20. The Denver TB Course
Sponsor: National Jewish Health
Dates: October 12 – 15, 2011
Location: Denver, Colorado
The purpose of this course is to present knowledge about the management of TB
to general internists, public health workers, infectious diseases and chest
specialists, registered nurses, and other healthcare providers who will be
responsible for the management and care of patients with TB. This event
includes the following course highlights: Transmission and pathogenesis of
adult and pediatric TB; MDR TB and XDR TB; Screening for and treatment of
latent TB infection; Factors influencing TB infections; Planning TB control
programs with particular emphasis on organization of outpatient chemotherapy;
TB and HIV co-infection; and Mycobacteriology Laboratory Tour.
Continuing education credits are available.
For more information contact Nicole Austin Ross, National Jewish Health, E-
mail: rossn@njhealth.org;
Phone: (303) 398-1110; Fax: (303) 270-2239; or access the Web site:
http://www.njhealth.org/TBCourse.